Patents by Inventor Trinayan Kashyap

Trinayan Kashyap has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
    Publication number: 20250059158
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: February 23, 2024
    Publication date: February 20, 2025
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shedhter
  • Nuclear transport modulators and uses thereof
    Patent number: 11945794
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: April 2, 2024
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
    Publication number: 20220177445
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: August 23, 2021
    Publication date: June 9, 2022
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Nuclear transport modulators and uses thereof
    Patent number: 11124493
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: September 21, 2021
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
    Publication number: 20200199099
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: July 23, 2019
    Publication date: June 25, 2020
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Nuclear transport modulators and uses thereof
    Patent number: 10407405
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: September 10, 2019
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • NUCLEAR TRANSPORT MODULATORS AND USES THEREOF
    Publication number: 20180155317
    Abstract: The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula I or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: July 17, 2017
    Publication date: June 7, 2018
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Nuclear transport modulators and uses thereof
    Patent number: 9738624
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula (I) or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: August 22, 2017
    Assignee: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter
  • Nuclear Transport Modulators and Uses Thereof
    Publication number: 20160152596
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the compounds of formula (I) or their pharmaceutically acceptable salts, and methods of using said compounds, salts and compositions in the treatment of various disorders associated with CRM1 activity.
    Type: Application
    Filed: June 20, 2014
    Publication date: June 2, 2016
    Applicant: Karyopharm Therapeutics Inc.
    Inventors: Erkan Baloglu, Sharon Shacham, Dilara McCauley, Trinayan Kashyap, William Senapedis, Yosef Landesman, Gali Golan, Ori Kalid, Sharon Shechter